

List of Contents

Title	Page
▪ List of Contents	I
▪ List of Tables	II
▪ List of Figures	V
▪ List of Abbreviations	VIII
▪ Introduction	1
▪ Aim of the Work	2
▪ Review of Literature:	
0 Chapter (I): Renal transplantation.....	3
0 Chapter (II): HCV with Kidney transplantation	11
0 Chapter (III): Causes of HCV Seroconversion after Transplantation.....	19
0 Chapter (IV): Impact of HCV on Patient Survival and Graft Survival after Renal Transplantation	21
0 Chapter (V): Extrahepatic Complications Associated with Hepatitis C Virus Infection after Renal Transplantation	29
0 Chapter (VI): Immunosuppression in Hepatitis C Virus- Infected Patients after Kidney Transplantation	45
▪ Patients and Methods	55
▪ Results	59
▪ Discussion	85
▪ Summary and Conclusion	97
▪ References	101
▪ Arabic Summary	--

List of Tables

Table No.	Title	Page
Table (1):	Showed classification of stages of chronic kidney disease	4
Table (2):	Panels of tests used to detect liver fibrosis in HCV+ patients with end-stage renal disease.....	28
Table (3):	Type of infectious syndrome and causative agent according to anti-HCV status	42
Table (4):	Comparison between Group A (HCV -ve, 40 patients) and Group B (HCV +ve, 40 patients) as regards age (years)	59
Table (5):	Comparison between Group A (HCV -ve, 40 patients) and Group B (HCV +ve, 40 patients) as regards gender distribution	60
Table (6):	Comparison between Group A (HCV -ve, 40 patients) and Group B (HCV +ve, 40 patients) as regard dialysis therapy before transplantation.....	61
Table (7):	Comparison between Group A (HCV -ve, 40 patients) & Group B (HCV +ve, 40 patients) as regards the duration of dialysis therapy before transplantation (years).....	62

List of Tables (Cont.)

Table No.	Title	Page
Table (8):	Comparison between Group A and group B as regards serum creatinine, blood urea, AST, ALT and serum albumin in group A and group B.....	64
Table (9):	Comparison of age & gender between Group A1 & Group B & Group C	67
Table (10):	Comparison of the dialysis therapy before transplantation in Group A1, group B & group C	69
Table (11):	Comparison of the dialysis therapy duration before transplantation in Group A1, group B & group C	70
Table (12):	The frequency of different immune-suppressive drugs between the 3 groups	73
Table (13):	Comparison between Group A1, Group B, and Group C as regards serum creatinine, blood urea, AST, ALT, and serum albumin	75
Table (14):	Comparison between the 3 groups as regard AST, Group B, and Group C	76
Table (15):	Comparison between the 3 groups as regard ALT, Group B, and Group C	76
Table (16):	Comparison between the 3 groups as regard Serum Albumin, Group B, and Group C	77
Table (17):	Comparison between the 3 groups as regard duration of transplantation	79

List of Tables (Cont.)

Table No.	Title	Page
Table (18):	Comparison between the 3 groups as regard acute rejection	80
Table (19):	Correlation between different laboratory parameters in all the eighty kidney transplanted patients included in the study	82
Table (20):	Correlation between different laboratory parameters in all patients of HCV -ve group A (40 patients).....	83
Table (21):	Correlation between different laboratory parameters in all patients of HCV +ve group B (40 patients)	84

List of Figures

Figure No.	Title	Page
Figure (1):	Decline in functional status associated with institution of dialysis, recovery, then a secondary decline associated with transplantation	6
Figure (2):	Estimating per-month expenditures for patients aged 45 to 64.....	8
Figure (3):	Impact of duration of time undergoing dialysis on allograft survival at 10 years after transplantation	9
Figure (4):	Algorithm for evaluation and management of chronic HCV infection in patients who are under consideration for kidney transplantation.....	15
Figure (5):	Histological features of HCV- related de novo MPGN after renal transplantation.....	36
Figure (6):	Innate immunity and HCV- associated glomerulonephritis	39
Figure (7):	Comparison between group A & B as regard the age.....	59
Figure (8):	Gender distribution in group A & B.....	60
Figure (9):	Hemodialysis therapy in group A & B before transplantation.....	61
Figure (10):	Duration of dialysis before kidney transplantation in group A & B	62

List of Figures (Cont.)

Figure No.	Title	Page
Figure (11):	Comparison of blood transfusion before transplantation in HCV -ve Group A (40 patients) and HCV +ve Group B (40 patients).....	63
Figure (12):	Comparison between group A & B as regard s. creatinine, urea, AST, ALT & s. Albumin	64
Figure (13):	The rate of HCV seroconversion after transplantation in group A (HCV -ve, 40 patients) & group B (HCV +ve, 40 patients) as detected by HCV antibodies (ELISA 3rd generation).....	65
Figure (14):	Percentage of seroconversion in group A & B.....	65
Figure (15):	Age in groups A, B& C.....	67
Figure (16):	Gender distribution in group A, B & C.....	68
Figure (17):	The dialysis therapy before transplantation in group A, B & C.....	69
Figure (18):	Duration of dialysis before transplantation in group A, B & C	70
Figure (19):	Comparison of hemodialysis therapy after transplantation between Group A1 & group C	71
Figure (20):	Comparison in blood transfusion after transplantation between Group A1 & group C.....	72

List of Figures (Cont.)

Figure No.	Title	Page
Figure (21):	Immunosuppressive drugs in group A, B & C.....	73
Figure (22):	Comparison between group A, B & C as regard s. creatinine, urea, AST, ALT & s. Albumin	75
Figure (23):	Duration of transplantation in group A, B & C.....	79
Figure (24):	Acute rejection in group A, B & C	80

List of Abbreviation

ALT		Alanine Aminotransferase		
AST		Aspartate Aminotransferase		
ATG		Anti thymocyte globulin		
CKD		Chronic Kidney Disease.		
CNI		Calcineurin inhibitors.		
ESRD		End Stage Renal Disease.		
GFR		Glomerular Filtration Rate.		
HBV		Hepatitis B virus.		
HCV		Hepatitis C virus.		
HD		Hemodialysis.		
K/DOQI		Kidney Disease Outcome Initiative.	Quality	
KDIGO		Kidney Disease Improving Outcomes.	Global	
MMF		Mycophenolate Mofetil.		
MPGN		Membrano- Glomerulonephritis.	Proliferative	
mTOR		mammalian Target Of Rapamycin.		
NAT		Nucleic acid Amplification Technique.		
NKF		National Kidney Foundation.		
NODAT		Neo Onset Diabetes After Transplantation.		
PCR		Polymerase chain reaction		
RRT		Renal Replacement Therapy.		
RT		Renal Transplantation		
SRTR		the Scientific Registry of Transplant Recipients		

Introduction

Kidney transplantation is renal replacement modality of choice for ESRD and is associated with lower mortality and improved quality of life compared with chronic dialysis treatment (***Tonelli et al., 2011***).

HCV infection is a risk factor for graft loss and death in the long term with a higher rate of post-transplant complications (***Morales et al., 2004***).

Egypt has the highest prevalence of antibodies to hepatitis C virus (HCV) in the world estimated nationally at 14.7% and more than 500,000 new HCV infections per year were estimated, iatrogenic transmission is the most likely (***Miller and Abu Raddad, 2010***).

The prevalence of anti- HCV antibodies among kidney recipients living in different countries varies between 2.6% and 66% .it is also different between centers and geographic areas (***Moghaddam et al., 2008***). The prevalence in Egypt according to the Egyptian renal registry is 52.1 % (***Afifi, 2008***).

The literature is poor in studies relevant to the prevalence of HCV and HCV seroconversion after kidney transplantation in our country.

Aim of the Work

The aim of this work is to evaluate the rate of HCV seroconversion after kidney transplantation in single center in Egypt (Nasr city insurance hospital kidney transplantation outpatient clinic) and its possible causes as well as the impact of HCV and conversion on relevant biochemical markers.



Chapter (I): Renal transplantation

The definition of chronic kidney disease (CKD) has been simplified over the last 5 years. It is now defined as the presence of kidney damage for a period greater than 3 months. An estimated or measured glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m² is considered abnormal for all adults. A rate of more than 60 ml/min/1.73 m² is considered abnormal if it is accompanied by abnormalities of urine sediment or abnormal results of imaging tests, or if the patient has had a kidney biopsy with documented abnormalities. As the reporting of estimated GFR has become more common, the relatively high prevalence of impaired kidney function (i.e., estimated GFR < 60 ml/min/1.73 m²) has become evident. The National Kidney Foundation (NKF) in the United States has published a classification system based on GFR as well as urinary and anatomic abnormalities (table 1) to enhance the identification and management of CKD (*Levin et al., 2008*).

Table (1): Showed classification of stages of chronic kidney disease (*Levin et al., 2008*)

Classification of stages of chronic kidney disease		
Stage	Description	GFR ML/min/1.73M ²
1	Kidney damage with normal or increased GFR	≥ 90
2	Kidney damage with mild decrease in GFR	60-89
3	Moderate decrease in GFR	30-59
4	Severe decrease in GFR	15-29
5	Kidney failure	<15 Or dialysis

General management of CKD:

The general management of the patient with chronic kidney disease involves the following issues:

1. Treatment of reversible causes of renal dysfunction.
2. Preventing or slowing the progression of renal disease.
3. Treatment of the complications of renal dysfunction.
4. Identification and adequate preparation of the patient in whom renal replacement therapy (RRT) will be required (*Schieppati et al., 2005*).

Once it is determined that RRT will eventually be required, the patient should be counseled to consider the advantages and disadvantages of haemodialysis (in-center or at home), peritoneal dialysis (continuous or intermittent modalities), and renal transplantation (living or deceased donor). The 2006 kidney disease outcomes quality initiative



(K/DOQI) guidelines recommend that patients with a GFR less than 30 ml/min per 1.73 m² should be educated concerning these issues (*K/DOQI Guidelines, 2006*).

Kidney transplantation is the treatment of choice for end-stage renal disease. A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients, when compared with maintenance dialysis. To facilitate early transplantation, a 2008 National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) conference suggested early education and referral to a transplantation center plus the identification of potential living donors (*Abecassis et al., 2008*).

Advantages of renal transplantation

It is now well established that early kidney transplantation is associated with optimal outcomes in terms of patient and graft survival. Not as widely appreciated is the potential salutary impact of preemptive transplantation on peaks (in cost, morbidity, and mortality) and valleys (in employability and quality of life) that occur with transitions in CKD care (Fig. 1) Whereas mortality within the first year of initiation of RRT has steadily declined for patients who are on peritoneal dialysis and those who receive transplants, early mortality on haemodialysis remains high and relatively unchanged since the mid-1990s . Furthermore, of patients who were on dialysis for 1 yr, only 24% returned to work after transplantation, compared



with at least one half of those who received a transplant preemptively. A key benefit of preemptive transplantation may therefore reside in avoiding these coincident positive and negative peaks in mortality and quality of life, respectively, by smoothing the transition to RRT, for an appropriate candidate, “Transplant First” should always be the goal (*Abecassis, et al., 2008*).




Fig. (1): Decline in functional status associated with institution of dialysis, recovery, then a secondary decline associated with transplantation. Preemptive transplantation has the potential to decrease substantially the adverse impact of RRT on quality-of-life measures (**NKF/KDOQI Conference on Early Kidney Transplantation, Washington, DC, (Abecassis, et al 2008).**



Renal transplantation

The underlying reasons for improved survival with renal transplantation compared with dialysis are unclear. However, since a functioning renal allograft more closely resembles a normal kidney than does maintenance dialysis therapy, it is possible that the survival benefit may result in part from improved clearance of uremic toxins. A possibility is that the recovery of renal function with a functional renal allograft lowers the inflammatory and/or oxidative state found in patients undergoing chronic dialysis. This has been reported in some studies for levels of C-reactive protein (**CRP**), tumor necrosis factor –alpha (**TNF- α**) and interleukin-6 (*Cueto-Manzano, et al., 2005*).

Overall, costs attributable to maintenance of a kidney transplant are less than one third those that are associated with long-term dialysis. It is now clear that transplants performed preemptively reduce the frequency of costly complications such as delayed graft function, acute rejection, and allograft failure. Although available estimates remain inexact, it is likely that by also avoiding the initiation of dialysis with its attendant complications, preemptive transplantation imparts substantial cost savings to the Medicare ESRD program.

Estimates performed by Eugene Schweitzer (**Figure 2**) indicated that the lengthier the period of dialysis avoided, the greater the cost savings to be realized (*Innocenti, et al., 2007*).

For appropriate candidates, kidney transplantation from a living donor or deceased donor provides the best outcomes among available modalities of RRT; time spent on dialysis